CoChat

Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression

Open access
Albring, Jörn C., Sandau, Michelle M., Rapaport, Aaron S., Edelson, Brian T., Satpathy, Ansuman, Mashayekhi, Mona, Lathrop, Stephanie K., Hsieh, Chyi-Song, Stelljes, Matthias, Colonna, Marco, Murphy, Theresa L., Murphy, Kenneth M. · 2010 · Journal of Experimental Medicine
Cited by 68

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Graft-versus-host disease (GVHD) causes significant morbidity and mortality in allogeneic hematopoietic stem cell transplantation (aHSCT), preventing its broader application to non–life-threatening diseases. We show that a single administration of a nondepleting monoclonal antibody specific for the coinhibitory immunoglobulin receptor, B and T lymphocyte associated (BTLA), permanently prevented GVHD when administered at the time of aHSCT. Once GVHD was established, anti-BTLA treatment was unable to reverse disease, suggesting that its mechanism occurs early after aHSCT. Anti-BTLA treatment prevented GVHD independently of its ligand, the costimulatory tumor necrosis factor receptor herpesvirus entry mediator (HVEM), and required BTLA expression by donor-derived T cells. Furthermore, anti-BTLA treatment led to the relative inhibition of CD4+ forkhead box P3− (Foxp3−) effector T cell (T eff cell) expansion compared with precommitted naturally occurring donor-derived CD4+ Foxp3+ regulatory T cell (T reg cell) and allowed for graft-versus-tumor (GVT) effects as well as robust responses to pathogens. These results suggest that BTLA agonism rebalances T cell expansion in lymphopenic hosts after aHSCT, thereby preventing GVHD without global immunosuppression. Thus, targeting BTLA with a monoclonal antibody at the initiation of aHSCT therapy might reduce limitations imposed by histocompatibility and allow broader application to treatment of non–life-threatening diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20102017

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Hematopoietic Stem-Cell Transplantation

    Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522 · cited 2×

    “Replacement of an abnormal lymphohemato­ poietic system by allogeneic hematopoietic stem cell transplantation (aHSCT) from a healthy donor is an effective treatment for many dis­ orders of the hematopoietic system (Sykes and Nikolic, 2005; Copelan, 2006).”
    Background
  • BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

    Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · cited 6×

    “RESULTS AND DISCUSSION To determine the role of BTLA in the development of GVHD, we first examined WT and BTLA/ donor mice (Watanabe et al., 2003) using a nonlethal parent­into­irradiated F1 model of aHSCT (Stelljes et al.”
    BackgroundMethodInfluentialSelf-citation
  • Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA

    Gavrieli, M., & Murphy, K. M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.036 · Cited by 85 · cited 2×

    “Although the precise molecular targets of BTLA signaling are still obscure (Gavrieli and Murphy, 2006; Wu et al., 2007), BTLA engagement by HVEM can inhibit T cell pro liferation in vitro (Sedy et al., 2005) and promote tolerance induction in vivo (Liu et al., 2009).”
    BackgroundSelf-citation

Show all 3 references

Cited by

See all 68

Metadata

Authors
Albring, J. C., Sandau, M. M., Rapaport, A. S., Edelson, B. T., Satpathy, A., Mashayekhi, M., Lathrop, S. K., Hsieh, C.-S., Stelljes, M., Colonna, M., Murphy, T. L., & Murphy, K. M.
Venue
Journal of Experimental Medicine
Published
2010-11-15
Volume
207
Issue
12
Pages
2551-2559
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2131387566
Cited by
68
References
3
FWCI
3.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. https://app.cochat.ai/papers/10.1084/jem.20102017
The paper
Albring, J. C., Sandau, M. M., Rapaport, A. S., Edelson, B. T., Satpathy, A., Mashayekhi, M., Lathrop, S. K., Hsieh, C.-S., Stelljes, M., Colonna, M., Murphy, T. L., & Murphy, K. M. (2010). Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20102017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.